JP2016514248A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514248A5
JP2016514248A5 JP2015557203A JP2015557203A JP2016514248A5 JP 2016514248 A5 JP2016514248 A5 JP 2016514248A5 JP 2015557203 A JP2015557203 A JP 2015557203A JP 2015557203 A JP2015557203 A JP 2015557203A JP 2016514248 A5 JP2016514248 A5 JP 2016514248A5
Authority
JP
Japan
Prior art keywords
tumor
low
kit
risk classification
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514248A (ja
JP6576249B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/015854 external-priority patent/WO2014124454A1/en
Publication of JP2016514248A publication Critical patent/JP2016514248A/ja
Publication of JP2016514248A5 publication Critical patent/JP2016514248A5/ja
Application granted granted Critical
Publication of JP6576249B2 publication Critical patent/JP6576249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557203A 2013-02-11 2014-02-11 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用 Expired - Fee Related JP6576249B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763266P 2013-02-11 2013-02-11
US61/763,266 2013-02-11
US201361883802P 2013-09-27 2013-09-27
US61/883,802 2013-09-27
PCT/US2014/015854 WO2014124454A1 (en) 2013-02-11 2014-02-11 Use of facilitates chromatin transcription complex (fact) in cancer

Publications (3)

Publication Number Publication Date
JP2016514248A JP2016514248A (ja) 2016-05-19
JP2016514248A5 true JP2016514248A5 (enExample) 2017-03-16
JP6576249B2 JP6576249B2 (ja) 2019-09-18

Family

ID=51300203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557203A Expired - Fee Related JP6576249B2 (ja) 2013-02-11 2014-02-11 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用

Country Status (6)

Country Link
US (1) US10386370B2 (enExample)
EP (1) EP2954331B1 (enExample)
JP (1) JP6576249B2 (enExample)
CN (1) CN104981697B (enExample)
EA (1) EA036615B1 (enExample)
WO (1) WO2014124454A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108333366B (zh) * 2018-01-26 2020-06-12 南通大学附属医院 一种实验性监测肝细胞恶性转化过程大鼠模型的建立方法
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN113721020B (zh) * 2021-09-14 2022-06-24 大连医科大学附属第二医院 Ctsf在非小细胞肺癌诊断中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2715680A1 (de) 1977-04-07 1978-10-12 Henkel Kgaa Haarfaerbemittel
DK2258872T3 (da) 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US20100047783A1 (en) 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2009055823A2 (en) * 2007-10-26 2009-04-30 Progen Pharmaceuticals Limited Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
EA021331B1 (ru) 2008-05-20 2015-05-29 Общество С Ограниченной Ответственностью "Инкурон" Индуцирование клеточной гибели путем ингибирования адаптивной реакции теплового шока
US20100081666A1 (en) 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
EA028630B1 (ru) 2012-03-27 2017-12-29 ИНКУРОН ЭлЭлСи Способ предотвращения вызванного канцерогеном рака с применением кураксина-137
US20140066465A1 (en) 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Similar Documents

Publication Publication Date Title
Graziano et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
Maly et al. Circulating tumor cells in diagnosis and treatment of lung cancer
Kuhlmann et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance
Alamgeer et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
Kondalsamy-Chennakesavan et al. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age
Espinosa-Bravo et al. Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay
Ding et al. Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis
Sonnenblick et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
Lee et al. Circulating tumor cells in breast cancer: applications in personalized medicine
Hu et al. The upregulation of trophinin-associated protein (TROAP) predicts a poor prognosis in hepatocellular carcinoma
Lassus et al. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma
JP2012524278A (ja) がんの臨床診断および予後診断のためのヒストン修飾パターン
Szarvas et al. High insulin‐like growth factor mRNA‐binding protein 3 (IMP3) protein expression is associated with poor survival in muscle‐invasive bladder cancer
Hokka et al. Psf3 is a prognostic biomarker in lung adenocarcinoma
US10267802B2 (en) Methods of prognosis and diagnosis of ovarian cancer
Honing et al. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy
Fan et al. Immunostaining with EGFR mutation–specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples
Augustin et al. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer
Yang et al. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma
JP2016536568A5 (enExample)
Franceschini et al. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology
Wang et al. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy
Vasilevska et al. Cytokeratin expression pattern in human endometrial carcinomas and lymph nodes micrometastasis: a mini-review
Babar et al. Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma
Bode et al. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors